The Relationship Between Patient Knowledge of Hemoglobin Levels and Health-Related Quality of Life
- 1 February 2006
- journal article
- Published by Springer Science and Business Media LLC in Quality of Life Research
- Vol. 15 (1), 57-68
- https://doi.org/10.1007/s11136-005-8324-0
Abstract
Background: An anti-anemia drug may improve self-reported quality of life (QOL) partly because patients know their hemoglobin level is rising. In the absence of any published studies on this topic, the authors investigated the association between knowledge of hemoglobin levels and self-reported QOL.Methods: The study analyzed health-related QOL (HRQOL) data from five randomized clinical trials of erythropoietic therapy in patients with cancer-related anemia. Patients were asked whether they knew their hemoglobin level and, if so, to report its value. Patients (n = 1007) were grouped into three categories depending on the extent and accuracy of hemoglobin level knowledge. HRQOL scale scores were compared between categories.Results: Only 23.2% of patients reported knowing their hemoglobin level at the end of the study; however, the value was accurate (within 1 g/dl) in 88.0% of these patients. On five of the 11 HRQOL scales studied, there was a significant association between knowledge of hemoglobin level and HRQOL score. However, the magnitude of the mean difference between those who knew vs. those who did not know their hemoglobin was generally below scale thresholds for minimally important differences. Conclusions: Patient knowledge of hemoglobin level has a modest association with some aspects of self-reported HRQOL. The magnitude of this association, where it exists, would be unlikely to explain large group differences in HRQOL reports over time, even for patients who know their hemoglobin level.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled studyBritish Journal of Haematology, 2003
- Health-related quality of life of subjects with known and unknown hypertensionJournal of Hypertension, 2003
- A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant diseaseCancer, 2003
- Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfaEuropean Journal Of Cancer, 2003
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving ChemotherapyJNCI Journal of the National Cancer Institute, 2002
- Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapyBritish Journal of Cancer, 2002
- Epoetin alfa in patients not on chemotherapy – Canadian dataSeminars in Oncology, 2002
- Fatigue in cancer patients compared with fatigue in the general United States populationCancer, 2002
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJournal of Pain and Symptom Management, 1997